Citations

Clear

959 citation(s) found for "Service, F J".

Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
Wen, Patrick Y. , Weller, Michael , Lee, Eudocia Q. , Barnholtz‐Sloan, Jill S. , Barthel, Floris P , Batchelor, Tracy T. , Chang, Susan M. , DeGroot, John, Hegi, Monika E. , Huang, Raymond Y. , Lassman, Andrew B. , Lim, Michael , Mellinghoff, Ingo K. , Minniti, Giuseppe , Nathanson, David A. , Platten, Michael , Preusser, Matthias , Roth, Patrick , Sanson, Marc , Schiff, David , Short, Susan , Taphoorn, Martin , Tonn, Joerg-Christian, Tsang, Jonathan , Verhaak, Roel G.W. , Deimling, Andreas von , Zadeh, Gelareh , Reardon, David A. , Aldape, Kenneth , Bent, Martin J. van den , Weller, Michael , Short, Susan C , van den Bent, Martin J , Barnholtz-Sloan, Jill S , Platten, Michael , Preusser, Matthias , Sanson, Marc , von Deimling, Andreas , Mellinghoff, Ingo K , Huang, Raymond , Roth, Patrick , Barthel, Floris P , Wen, Patrick Yung , Alexander, Brian M. , Bindra, Ranjit S. , Chiocca, E Antonio , Cloughesy, Timothy F. , Galanis, Evanthia , Gilbert, Mark R. , Horbinski, Craig , Rhun, Émilie Le , Mehta, Minesh P. , Tonn, Joerg-Christian , Wick, Wolfgang

Mayo Clinic

Neuro-Oncology | April 20, 2020 | Volume: 22 | Issue: 8 | Pages: 1073-1113

10.1093/neuonc/noaa106 | PMID 32328653 Get It

Abstract Glioblastomas are the most common form of malignant primary brain tumor and an important cause of morbidity and mortality. In recent years there have been important advances in understanding the molecular pathogenesis and biology of these tumors, but this has not translated into significantly improved outcomes for patients. In this consensus review from the Society for Neuro-Oncology (SNO) and the European Association of Neuro-Oncology (EANO), the current management of isocitrate dehydrogenase wildtype (IDHwt) glioblastomas will be discussed. In addition, novel therapies such as targeted molecular therapies, agents targeting DNA damage response and metabolism, immunotherapies, and viral therapies will be reviewed, as well as the current challenges and future directions for research.
cIMPACT‐NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT‐Utrecht meeting on future CNS tumor classification and grading
Louis, David N. , Wesseling, Pieter , Aldape, Kenneth , Capper, David , Cree, Ian A. , Figarella‐Branger, Dominique , Fouladi, Maryam, Haberler, Christine , Hawkins, Cynthia , Komori, Takashi, Ng, Ho‐Keung , Orr, Brent A. , Paulus, Werner, Pietsch, Torsten , Reifenberger, Guido , Rosenblum, Marc, Rous, Brian , Sahm, Felix , Sarkar, Chitra , Solomon, David A. , Tabori, Uri , Bent, Martin J. van den , Deimling, Andreas von , Weller, Michael , White, Valerie A. , Ellison, David W. , Figarella-Branger, Dominique , Pietsch, Torsten , Sarkar, Chitra , Solomon, David A , Weller, Michael , van den Bent, Martin J , Orr, Brent A , Wesseling, Pieter , von Deimling, Andreas , Tabori, Uri , Sahm, Felix , Capper, David , Brat, Daniel J. , Eberhart, Charles G. , Fouladi, Maryam , Fuller, Gregory N. , Giannini, Caterina , Kros, Johan M. , Park, Sung-Hye , Perry, Arie , Rosenblum, Marc

Mayo Clinic

Brain Pathology | April 20, 2020 | Volume: 30 | Issue: 4 | Pages: 844-856

10.1111/bpa.12832 | PMID 32307792 Get It

Abstract cIMPACT‐NOW (the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy) was established to evaluate and make practical recommendations on recent advances in the field of CNS tumor classification, particularly in light of the rapid progress in molecular insights into these neoplasms. For Round 2 of its deliberations, cIMPACT‐NOW Working Committee 3 was reconstituted and convened in Utrecht, The Netherlands, for a meeting designed to review putative new CNS tumor types in advance of any future World Health Organization meeting on CNS tumor classification. In preparatory activities for the meeting and at the actual meeting, a list of possible entities was assembled and each type and subtype debated. Working Committee 3 recommended that a substantial number of newly recognized types and subtypes should be considered for inclusion in future CNS tumor classifications. In addition, the group endorsed a number of principles—relating to classification categories, approaches to classification, nomenclature, and grading—that the group hopes will also inform the future classification of CNS neoplasms.
Essential Role of Patient Blood Management in a Pandemic: A Call for Action
Shander, Aryeh , Goobie, Susan M. , Aapro, Matti , Bisbe, Elvira , Callum, Jeannie , Erhard, J., Faraoni, David , Farmer, Shannon L. , Федорова, Т. А. , Gombotz, H., Gross, Irwin, Guinn, Nicole R. , Hamdorf, Jeffrey M. , Isbister, James P. , Ji, Hongwen , Kor, Daryl J. , Kurz, Johann, Lasocki, Sigismond , Leahy, Michael F. , Lee, Cheuk‐Kwong, Lee, Jeong Jae , Louw, Vernon , Meier, Jens , Mezzacasa, Anna, Múñoz, Manuel , Ozawa, Sherri , Pavesi, Marco , Shander, Nina, Spiess, Bruce D. , Thomson, Jackie, Trentino, Kevin M. , Zenger, Christoph, Hofmann, Axel , Warner, Matthew A. , Pérez-Calatayud, Ángel Augusto , Cushing, Melissa M. , Dyer, Wayne Bruce , Frank, Steven M. , Froessler, Bernd , Haas, Thorsten , Javidroozi, Mazyar , Kim, Young‐Woo , Lee, Cheuk Kwong , Spahn, Donat R. , Zenger, Christoph

Mayo Clinic

Anesthesia & Analgesia | April 2, 2020 | Volume: 131 | Issue: 1 | Pages: 74-85

10.1213/ane.0000000000004844 | PMID 32243296 Get It

The World Health Organization (WHO) has declared coronavirus disease 2019 (COVID-19), the disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a pandemic. Global health care now faces unprecedented challenges with widespread and rapid human-to-human transmission of SARS-CoV-2 and high morbidity and mortality with COVID-19 worldwide. Across the world, medical care is hampered by a critical shortage of not only hand sanitizers, personal protective equipment, ventilators, and hospital beds, but also impediments to the blood supply. Blood donation centers in many areas around the globe have mostly closed. Donors, practicing social distancing, some either with illness or undergoing self-quarantine, are quickly diminishing. Drastic public health initiatives have focused on containment and “flattening the curve” while invaluable resources are being depleted. In some countries, the point has been reached at which the demand for such resources, including donor blood, outstrips the supply. Questions as to the safety of blood persist. Although it does not appear very likely that the virus can be transmitted through allogeneic blood transfusion, this still remains to be fully determined. As options dwindle, we must enact regional and national shortage plans worldwide and more vitally disseminate the knowledge of and immediately implement patient blood management (PBM). PBM is an evidence-based bundle of care to optimize medical and surgical patient outcomes by clinically managing and preserving a patient’s own blood. This multinational and diverse group of authors issue this “Call to Action” underscoring “The Essential Role of Patient Blood Management in the Management of Pandemics” and urging all stakeholders and providers to implement the practical and commonsense principles of PBM and its multiprofessional and multimodality approaches.
Comprehensive germline mutation analysis and clinical profile in a large cohort of Brazilian xeroderma pigmentosum patients
Santiago, Karina Miranda , Castro, Ligia Pereira , Neto, João Pedreira Duprat , Nóbrega, Amanda França de , Pinto, C. A. L., Ashton‐Prolla, Patrícia , Vairo, Filippo Pinto e , Medeiros, Paula Frassinetti Vasconcelos de , Ribeiro, Erlane Marques , Ribeiro, Bethania F.R. , Doriqui, Maria Juliana R. , Leite, C.H.B. , Rocha, Rafael Malagoli , Moura, Livia Maria Silva , Menck, Carlos Frederico Martins , Rogatto, Sílvia Regina , Achatz, Maria Isabel , Santiago, K M , Castro, L P , Neto, J P D , de Nóbrega, A F , Ashton-Prolla, P , Vairo, Filippo , de Medeiros, P F V , Ribeiro, E M , Ribeiro, B F R , do Valle, F F , Leite, C H B , Rocha, R M , Moura, L M S , Munford, V , Galante, P A F , Menck, C F M , Rogatto, S R , Achatz, M I

Mayo Clinic

Journal of the European Academy of Dermatology and Venereology | April 2, 2020 | Volume: 34 | Issue: 10 | Pages: 2392-2401

10.1111/jdv.16405 | PMID 32239545 Get It

Abstract Background Xeroderma pigmentosum (XP) patients present a high risk of developing skin cancer and other complications at an early age. This disease is characterized by mutations in the genes related to the DNA repair system. Objectives To describe the clinical and molecular findings in a cohort of 32 Brazilian individuals who received a clinical diagnosis of XP. Methods Twenty‐seven families were screened for germline variants in eight XP‐related genes. Results All patients ( N = 32) were diagnosed with bi‐allelic germline pathogenic or potentially pathogenic variants, including nine variants previously undescribed. The c.2251‐1G>C XPC pathogenic variant, reported as the founder mutation in Comorian and Pakistani patients, was observed in 15 cases in homozygous or compound heterozygous. Seven homozygous patients for POLH/XPV variants developed their symptoms by an average age of 7.7 years. ERCC2 / XPD , DDB2 / XPE and ERCC5 / XPG variants were found in a few patients. Aside from melanoma and non‐melanoma skin tumours, a set of patients developed skin sebaceous carcinoma, leiomyosarcoma, angiosarcoma, mucoepidermoid carcinoma, gastric adenocarcinoma and serous ovarian carcinoma. Conclusions We reported a high frequency of XPC variants in 32 XP Brazilian patients. Nine new variants in XP‐related genes, unexpected non‐skin cancer lesions and an anticipation of the clinical manifestation in POLH/XPV cases were also described.
Acute Effects of Glucagon on Reproductive Hormone Secretion in Healthy Men
Izzi‐Engbeaya, Chioma , Jones, Sophie , Crustna, Yoshibye, Machenahalli, Pratibha, Papadopoulou, Deborah , Starikova, Jessica , Chan, Derek , Eng, Pei Chia , Ratnasabapathy, Risheka , Mills, Edouard , Yang, Lisa, Pacuszka, Ewa, Bech, Paul, Tharakan, George, Tan, Tricia , Veldhuis, Johannes D. , Abbara, Ali , Comninos, Alexander , Dhillo, Waljit S. , Veldhuis, Johannes, Modi, Manish , Phylactou, Maria , MINNION, JAMES S.

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | March 31, 2020 | Volume: 105 | Issue: 6 | Pages: 1899-1905

10.1210/clinem/dgaa164 | PMID 32232363 Get It

Abstract Context Glucagon increases energy expenditure; consequently, glucagon receptor agonists are in development for the treatment of obesity. Obesity negatively affects the reproductive axis, and hypogonadism itself can exacerbate weight gain. Therefore, knowledge of the effects of glucagon receptor agonism on reproductive hormones is important for developing therapeutics for obesity; but reports in the literature about the effects of glucagon receptor agonism on the reproductive axis are conflicting. Objective The objective of this work is to investigate the effect of glucagon administration on reproductive hormone secretion in healthy young men. Design A single-blinded, randomized, placebo-controlled crossover study was conducted. Setting The setting of this study was the Clinical Research Facility, Imperial College Healthcare NHS Trust. Participants Eighteen healthy eugonadal men (mean ± SEM: age 25.1 ± 1.0 years; body mass index 22.5 ± 0.4 kg/m2; testosterone 21.2 ± 1.2 nmol/L) participated in this study. Intervention An 8-hour intravenous infusion of 2 pmol/kg/min glucagon or rate-matched vehicle infusion was administered. Main Outcome Measures Luteinizing hormone (LH) pulsatility; LH, follicle-stimulating hormone (FSH), and testosterone levels were measured. Results Although glucagon administration induced metabolic effects (insulin area under the curve: vehicle 1065 ± 292 min.µU/mL vs glucagon 2098 ± 358 min.µU/mL, P < .001), it did not affect LH pulsatility (number of LH pulses/500 min: vehicle 4.7 ± 0.4, glucagon 4.2 ± 0.4, P = .22). Additionally, there were no significant differences in circulating LH, FSH, or testosterone levels during glucagon administration compared with vehicle administration. Conclusions Acute administration of a metabolically active dose of glucagon does not alter reproductive hormone secretion in healthy men. These data are important for the continued development of glucagon-based treatments for obesity.
Author response: Characterising a healthy adult with a rare HAO1 knockout to support a therapeutic strategy for primary hyperoxaluria
McGregor, Tracy L., Yee, Elaine, Nioi, Paul , Ticau, Simina , Pelosi, Marissa, Loken, Perry R , Lawlor, Deborah A, Huang, Qin , Erbe, David V., Hunt, Karen A. , Mason, Dan , Finer, Sarah , Lawlor, Deborah A, Fauman, Eric B. , Griffiths, Chris , MacArthur, Daniel G. , Trembath, Richard C. , Oglesbee, Devin , Lieske, John C. , Wright, John , Heel, David A. van

Mayo Clinic

No container title available | March 31, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.7554/elife.54363.sa2 Get It

American College of Clinical Pharmacy Global Health Practice and Research Network's opinion paper: Pillars for global health engagement and key engagement strategies for pharmacists
Crowe, Susie , Schellhase, Ellen , Miller, Monica L. , Abrons, Jeanine P., Alsharif, Naser Z., Andrade, Christina , Cope, Rebecca , Dornblaser, Emily K., Hachey, David M. , Holm, Michelle R., Jonkman, Lauren , Lukas, Stephanie , Malhotra, Jodie , Njuguna, Benson , Pekny, Chelsea, Prescott, Gina M. , Steeb, David R. , Tran, Dan N. , Karwa, Rakhi , Ryan, Melody A.

Mayo Clinic

JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY | March 31, 2020 | Volume: 3 | Issue: 6 | Pages: 1097-1112

10.1002/jac5.1232 Get It

AbstractThe scope of pharmacy practice in global health has expanded over the past decade creating additional education and training opportunities for students, residents and pharmacists. There has also been a shift from short‐term educational and clinical experiences to more sustainable bidirectional partnerships between high‐income countries (HICs) and low‐ to middle‐income countries (LMICs). As more institutional and individual partnerships between HICs and LMICs begin to form, it is clear that there is a lack of guidance for pharmacists on how to build meaningful, sustainable, and mutually beneficial programs. The aim of this paper is to provide guidance for pharmacists in HICs to make informed decisions on global health partnerships and identify opportunities for engagement in LMICs that yield mutually beneficial collaborations. This paper uses the foundations of global health principles to identify five pillars of global health engagement when developing partnerships: (a) sustainability, (b) shared leadership, (c) mutually beneficial partnerships, (d) local needs‐based care and (e) host‐driven experiential and didactic education. Finally, this paper highlights ways pharmacists can use the pillars as a framework to engage and support health care systems, collaborate with academic institutions, conduct research, and interface with governments to improve health policy.
At three years, patients with acute lymphoblastic leukaemia are still at risk for relapse. Results of the international MRC UKALLXII/ECOG E2993 trial
Ganzel, Chezi , Wang, Xin V., Rowe, Jacob M. , Richards, Susan , Buck, Georgina , Marks, David I. , Litzow, Mark R. , Paietta, Elisabeth , Foroni, Letizia, Luger, Selina M. , Wiernik, Peter H. , Douer, Dan , Tallman, Martin S. , Goldstone, Anthony H., Richards, Susan M., Willman, Cheryl L. , Mullighan, Charles G. , Roberts, Kathryn G. , Lazarus, Hillard M.

Mayo Clinic

British Journal of Haematology | March 27, 2020 | Volume: 191 | Issue: 1 | Pages: 37-43

10.1111/bjh.16616 | PMID 32220069 Get It

Summary Late relapse [>3 years from complete remission (CR)] in acute lymphoblastic leukaemia (ALL), is unusual. Data from the MRC UKALLXII/ECOG E2993 trial are presented to evaluate the incidence and characteristics of late relapse in adult ALL. Of 1,909 patients, 1,752 (92%) achieved CR and among these 757 (43·2%) relapsed; 691 (91·3%) within three years and 66 (8·7%) beyond. Among these 66 patients, median time to relapse was 47 (37–144) months. Relapse beyond three years occurred in 3·8% of all who achieved CR. The cumulative risk of relapse was 40%, 43% and 45% at three, five and ten years respectively. Out of the 1 752 patients who achieved CR, 11·7% underwent autologous and 40·6% allogeneic transplant, while in CR1. Of the autologous patients, 43·2% relapsed early and 3·4% relapsed late. However, among the allogeneic patients, 13·2% relapsed early and only 1·3% late. The five‐year overall survival from relapse was 5·8% and 20% in the early and late relapse patients respectively. In conclusion, late relapse in adults with ALL is not uncommon, and is associated with better outcome after relapse compared to early relapse.
Vulnerable plaques and patients: state-of-the-art
Katagiri, Yuki, Modolo, Rodrigo , Khamis, Ramzi , Bourantas, Christos V. , Torii, Ryo , Wentzel, Jolanda J. , Gijsen, Frank , Soest, Gijs van , Stone, Peter H. , West, Nick E.J. , Maehara, Akiko , Steen, Antonius F.W. van der , Lüscher, Thomas F. , Köenig, Wolfgang , Stone, Gregg W. , Muller, James E. , Onuma, Yoshinobu , Serruys, Patrick W , Onuma, Yoshinobu , Koenig, Wolfgang , Tomaniak, Mariusz , Silva, Ranil de , Lerman, Amir , Virmani, Renu , Wijns, William , Serruys, Patrick W.

Mayo Clinic

European Heart Journal | March 26, 2020 | Volume: 41 | Issue: 31 | Pages: 2997-3004

10.1093/eurheartj/ehaa227 | PMID 32402086 Get It

Abstract Despite advanced understanding of the biology of atherosclerosis, coronary heart disease remains the leading cause of death worldwide. Progress has been challenging as half of the individuals who suffer sudden cardiac death do not experience premonitory symptoms. Furthermore, it is well-recognized that also a plaque that does not cause a haemodynamically significant stenosis can trigger a sudden cardiac event, yet the majority of ruptured or eroded plaques remain clinically silent. In the past 30 years since the term ‘vulnerable plaque’ was introduced, there have been major advances in the understanding of plaque pathogenesis and pathophysiology, shifting from pursuing features of ‘vulnerability’ of a specific lesion to the more comprehensive goal of identifying patient ‘cardiovascular vulnerability’. It has been also recognized that aside a thin-capped, lipid-rich plaque associated with plaque rupture, acute coronary syndromes (ACS) are also caused by plaque erosion underlying between 25% and 60% of ACS nowadays, by calcified nodule or by functional coronary alterations. While there have been advances in preventive strategies and in pharmacotherapy, with improved agents to reduce cholesterol, thrombosis, and inflammation, events continue to occur in patients receiving optimal medical treatment. Although at present the positive predictive value of imaging precursors of the culprit plaques remains too low for clinical relevance, improving coronary plaque imaging may be instrumental in guiding pharmacotherapy intensity and could facilitate optimal allocation of novel, more aggressive, and costly treatment strategies. Recent technical and diagnostic advances justify continuation of interdisciplinary research efforts to improve cardiovascular prognosis by both systemic and ‘local’ diagnostics and therapies. The present state-of-the-art document aims to present and critically appraise the latest evidence, developments, and future perspectives in detection, prevention, and treatment of ‘high-risk’ plaques occurring in ‘vulnerable’ patients.
Characterising a healthy adult with a rare HAO1 knockout to support a therapeutic strategy for primary hyperoxaluria
McGregor, Tracy L., Yee, Elaine, Mason, Dan , Nioi, Paul , Ticau, Simina , Pelosi, Marissa, Loken, Perry R , Finer, Sarah , Lawlor, Deborah A, Fauman, Eric B. , Huang, Qin Qin , Griffiths, Chris , MacArthur, Daniel G. , Oglesbee, Devin , Erbe, David V., Heel, David A. van , Lawlor, Debbie A. , Finer, Sarah , Lieske, John C , van Heel, David A , Oglesbee, Devin , MacArthur, Daniel G , Hunt, Karen A. , Trembath, Richard C. , Lieske, John C. , Wright, John

Mayo Clinic

eLife | March 24, 2020 | Volume: 9 | Issue: No issue available | Pages: No page available

10.7554/elife.54363 | PMID 32207686 Get It

By sequencing autozygous human populations, we identified a healthy adult woman with lifelong complete knockout of HAO1 (expected ~1 in 30 million outbred people). HAO1 (glycolate oxidase) silencing is the mechanism of lumasiran, an investigational RNA interference therapeutic for primary hyperoxaluria type 1. Her plasma glycolate levels were 12 times, and urinary glycolate 6 times, the upper limit of normal observed in healthy reference individuals (n = 67). Plasma metabolomics and lipidomics (1871 biochemicals) revealed 18 markedly elevated biochemicals (>5 sd outliers versus n = 25 controls) suggesting additional HAO1 effects. Comparison with lumasiran preclinical and clinical trial data suggested she has <2% residual glycolate oxidase activity. Cell line p.Leu333SerfsTer4 expression showed markedly reduced HAO1 protein levels and cellular protein mis-localisation. In this woman, lifelong HAO1 knockout is safe and without clinical phenotype, de-risking a therapeutic approach and informing therapeutic mechanisms. Unlocking evidence from the diversity of human genetic variation can facilitate drug development.